Watson has received FDA approval for Ibandronate Sodium 150mg tablets, the generic version of Roche‘s Boniva. Ibandronate Sodium is a once monthly tablet indicated for the treatment and prevention of osteoporosis in postmenopausal women. Boniva was approved by the FDA in 2003. Watson intends to begin shipping the product in the second quarter of 2012.
Ibandronate Sodium, a bisphosphonate, is a specific inhibitor of osteoclast-mediated bone resorption. It acts as a chelator of calcium and has a high binding affinity for mineralized bone, which helps boost bone mass and reduce the risk for spinal fracture.
For more information call (800) 272-5525 or visit www.watson.com.